vs
Side-by-side financial comparison of Ameren (AEE) and Astrana Health, Inc. (ASTH). Click either name above to swap in a different company.
Ameren is the larger business by last-quarter revenue ($1.8B vs $950.5M, roughly 1.9× Astrana Health, Inc.). Ameren runs the higher net margin — 14.2% vs 0.7%, a 13.5% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs -8.2%). Astrana Health, Inc. produced more free cash flow last quarter ($-6.0M vs $-54.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs -0.9%).
Ameren Corporation, together with its subsidiaries, operates as a public utility holding company in the United States. It operates through four segments: Ameren Missouri, Ameren Illinois Electric Distribution, Ameren Illinois Natural Gas, and Ameren Transmission. The company engages in the rate-regulated electric generation, transmission, and distribution activities; and rate-regulated natural gas distribution and transmission businesses. It primarily generates electricity through coal, nucle...
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
AEE vs ASTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.8B | $950.5M |
| Net Profit | $253.0M | $6.6M |
| Gross Margin | — | — |
| Operating Margin | 20.2% | 1.9% |
| Net Margin | 14.2% | 0.7% |
| Revenue YoY | -8.2% | 42.9% |
| Net Profit YoY | 21.6% | 184.4% |
| EPS (diluted) | $0.92 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.8B | $950.5M | ||
| Q3 25 | $2.7B | $956.0M | ||
| Q2 25 | $2.2B | $654.8M | ||
| Q1 25 | $2.1B | $620.4M | ||
| Q4 24 | $1.9B | $665.2M | ||
| Q3 24 | $2.2B | $478.7M | ||
| Q2 24 | $1.7B | $486.3M | ||
| Q1 24 | $1.8B | $404.4M |
| Q4 25 | $253.0M | $6.6M | ||
| Q3 25 | $641.0M | $373.0K | ||
| Q2 25 | $277.0M | $9.4M | ||
| Q1 25 | $290.0M | $6.7M | ||
| Q4 24 | $208.0M | $-7.8M | ||
| Q3 24 | $457.0M | $16.1M | ||
| Q2 24 | $260.0M | $19.2M | ||
| Q1 24 | $262.0M | $14.8M |
| Q4 25 | 20.2% | 1.9% | ||
| Q3 25 | 30.6% | 2.0% | ||
| Q2 25 | 18.5% | 3.1% | ||
| Q1 25 | 20.5% | 3.3% | ||
| Q4 24 | 10.2% | 0.1% | ||
| Q3 24 | 27.0% | 5.9% | ||
| Q2 24 | 21.3% | 6.2% | ||
| Q1 24 | 20.4% | 7.5% |
| Q4 25 | 14.2% | 0.7% | ||
| Q3 25 | 23.7% | 0.0% | ||
| Q2 25 | 12.5% | 1.4% | ||
| Q1 25 | 13.8% | 1.1% | ||
| Q4 24 | 10.7% | -1.2% | ||
| Q3 24 | 21.0% | 3.4% | ||
| Q2 24 | 15.4% | 3.9% | ||
| Q1 24 | 14.4% | 3.7% |
| Q4 25 | $0.92 | $0.12 | ||
| Q3 25 | $2.35 | $0.01 | ||
| Q2 25 | $1.01 | $0.19 | ||
| Q1 25 | $1.07 | $0.14 | ||
| Q4 24 | $0.77 | $-0.14 | ||
| Q3 24 | $1.70 | $0.33 | ||
| Q2 24 | $0.97 | $0.40 | ||
| Q1 24 | $0.98 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.0M | $429.5M |
| Total DebtLower is stronger | $19.4B | — |
| Stockholders' EquityBook value | $13.4B | $779.3M |
| Total Assets | $48.5B | $2.2B |
| Debt / EquityLower = less leverage | 1.45× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.0M | $429.5M | ||
| Q3 25 | $9.0M | $463.4M | ||
| Q2 25 | $11.0M | $342.1M | ||
| Q1 25 | $23.0M | $260.9M | ||
| Q4 24 | $7.0M | $290.8M | ||
| Q3 24 | $17.0M | $350.3M | ||
| Q2 24 | $19.0M | $327.7M | ||
| Q1 24 | $85.0M | $337.3M |
| Q4 25 | $19.4B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $17.8B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $13.4B | $779.3M | ||
| Q3 25 | $12.8B | $775.5M | ||
| Q2 25 | $12.3B | $765.5M | ||
| Q1 25 | $12.2B | $745.4M | ||
| Q4 24 | $12.1B | $712.7M | ||
| Q3 24 | $11.8B | $704.6M | ||
| Q2 24 | $11.5B | $678.9M | ||
| Q1 24 | $11.4B | $653.5M |
| Q4 25 | $48.5B | $2.2B | ||
| Q3 25 | $47.4B | $2.2B | ||
| Q2 25 | $46.6B | $1.4B | ||
| Q1 25 | $45.7B | $1.3B | ||
| Q4 24 | $44.6B | $1.4B | ||
| Q3 24 | $43.3B | $1.3B | ||
| Q2 24 | $42.3B | $1.3B | ||
| Q1 24 | $41.3B | $1.2B |
| Q4 25 | 1.45× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.47× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $956.0M | $-2.9M |
| Free Cash FlowOCF − Capex | $-54.0M | $-6.0M |
| FCF MarginFCF / Revenue | -3.0% | -0.6% |
| Capex IntensityCapex / Revenue | 56.7% | 0.3% |
| Cash ConversionOCF / Net Profit | 3.78× | -0.44× |
| TTM Free Cash FlowTrailing 4 quarters | $-775.0M | $104.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $956.0M | $-2.9M | ||
| Q3 25 | $1.1B | $10.0M | ||
| Q2 25 | $862.0M | $90.9M | ||
| Q1 25 | $431.0M | $16.6M | ||
| Q4 24 | $817.0M | $-10.9M | ||
| Q3 24 | $897.0M | $34.0M | ||
| Q2 24 | $557.0M | $23.2M | ||
| Q1 24 | $492.0M | $6.0M |
| Q4 25 | $-54.0M | $-6.0M | ||
| Q3 25 | $116.0M | $7.4M | ||
| Q2 25 | $-204.0M | $89.5M | ||
| Q1 25 | $-633.0M | $13.6M | ||
| Q4 24 | $-473.0M | $-13.5M | ||
| Q3 24 | $-240.0M | $31.7M | ||
| Q2 24 | $-445.0M | $20.4M | ||
| Q1 24 | $-398.0M | $5.6M |
| Q4 25 | -3.0% | -0.6% | ||
| Q3 25 | 4.3% | 0.8% | ||
| Q2 25 | -9.2% | 13.7% | ||
| Q1 25 | -30.2% | 2.2% | ||
| Q4 24 | -24.4% | -2.0% | ||
| Q3 24 | -11.0% | 6.6% | ||
| Q2 24 | -26.3% | 4.2% | ||
| Q1 24 | -21.9% | 1.4% |
| Q4 25 | 56.7% | 0.3% | ||
| Q3 25 | 36.6% | 0.3% | ||
| Q2 25 | 48.0% | 0.2% | ||
| Q1 25 | 50.7% | 0.5% | ||
| Q4 24 | 66.5% | 0.4% | ||
| Q3 24 | 52.3% | 0.5% | ||
| Q2 24 | 59.2% | 0.6% | ||
| Q1 24 | 49.0% | 0.1% |
| Q4 25 | 3.78× | -0.44× | ||
| Q3 25 | 1.72× | 26.69× | ||
| Q2 25 | 3.11× | 9.65× | ||
| Q1 25 | 1.49× | 2.48× | ||
| Q4 24 | 3.93× | — | ||
| Q3 24 | 1.96× | 2.11× | ||
| Q2 24 | 2.14× | 1.21× | ||
| Q1 24 | 1.88× | 0.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AEE
Segment breakdown not available.
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
